In an interview with SonntagsZeitung, Novartis (NYSE:NVS)
CEO Vas Narasimhan says pre-clinical studies in animals as well as the
first data from clinical studies show that its hydroxychloroquine
malaria drug kills the coronavirus.
Vas Narasimhan says the company is working with
Swiss hospitals on possible treatment protocols for the clinical use of
the drug, “but it’s too early to say anything definitively.”
The CEO says Novartis is recruiting patients for
hydroxychloroquine in Europe and the U.S. for clinical studies, and is
in talks with regulatory authorities in the U.S. and Switzerland on
whether the company will be granted rapid approval.
Novartis has pledged to donate 130M doses and is
supporting clinical trials needed before the medicine, which Pres. Trump
also has been promoting, can be approved for use against COVID-19.
In addition to hydroxychloroquine, Narasimhan says
multiple sclerosis drug Gilenya, cancer drug Jakavi and fever drug
Ilaris are being tested in clinical studies.
https://seekingalpha.com/news/3556125-novartis-malaria-drug-biggest-hope-against-covidminus-19-ceo-says
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.